Subtype
Testicular Neoplasm
CI-CAN-00004087Explore in graph →
Non-malignant50 active trials3 approved drugs
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004087Explore in graph →
Clinical trials
286 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT02478502 | Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer | terminated | Phase 2 | 14 | University Hospital, AkershusOTHER | 4 | Feb 2, 2024 | clinicaltrials |
| NCT00788125 |
| Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors |
| terminated |
| Phase 1 / Phase 2 |
| 7 |
| City of Hope Medical CenterOTHER |
| 1 |
| Jul 14, 2023 |
| clinicaltrials |
| NCT02499952 | Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors | terminated | Phase 2 | 12 | Nasser Hanna, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT02689219 | Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors | terminated | Phase 2 | 18 | Nabil AdraOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT00531687 | Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer | terminated | Phase 2 | 8 | Rigshospitalet, DenmarkOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT00088881 | Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma | terminated | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | May 25, 2017 | clinicaltrials |
| NCT00003852 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | terminated | Phase 2 | 45 | UNICANCEROTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT01808534 | Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors | terminated | Phase 2 | 5 | Indiana UniversityOTHER | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00042952 | Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer | terminated | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Oct 17, 2024source: clinicaltrials